Patient specific treatment planning for systemically administered radiopharmaceuticals using PET/CT and Monte Carlo simulation

被引:5
作者
Grudzinski, J. J. [1 ]
Yoriyaz, H. [2 ]
DeLuca, P. M., Jr. [1 ]
Weichert, J. P. [1 ]
机构
[1] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA
[2] IPEN CNEN SP, Sao Paulo, Brazil
关键词
Radionuclide treatment planning; PET/CT; Monte Carlo; Patient specific dosimetry; LINEAR-QUADRATIC MODEL; TARGETED RADIONUCLIDE THERAPY; DOSE-RATE; THYROID-CANCER; I-124; PET; DOSIMETRY; RADIOTHERAPY; TUMOR; ATTENUATION; SPECT;
D O I
10.1016/j.apradiso.2009.09.070
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
The efficacy of systemically administered radiopharmaceuticals depends on the physiological path of the targeting molecule and the physical characteristics of the attached radionuclide. NM404 is a candidate for patient specific dosimetry because it can be used concurrently for both diagnosis and therapy. Radiolabeling NM404 with [I-124] affords the possibility of performing noninvasive PET imaging while [I-131] allows for radiotherapy. Patient specific dosimetry for radiation treatment planning for NM404 uses serial PET/CT data and Monte Carlo. [I-124]NM404 PET helps to determine the organ at risk by which the maximum injected activity of [I-131]NM404 will depend. The subsequent work uses a software interface (SCMS) to convert patient PET/CT data of a liver metastasis into a Monte Carlo environment for radiation transport analysis. Thereby, the dosimetry within the liver and tumor during both diagnostic and therapeutic procedures was determined. The results showed that per MBq injected of [I-124] and [I-131], the tumor receives an average of 1.2 and 1.5 mGy, respectively, while the liver receives 0.031 and 0.022 mGy, respectively. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:59 / 65
页数:7
相关论文
共 47 条
[1]  
Bai CY, 2003, J NUCL MED, V44, P1855
[2]  
Barone R, 2005, J NUCL MED, V46, p99S
[3]   Application of the linear-quadratic model to combined modality radiotherapy [J].
Bodey, RK ;
Evans, PM ;
Flux, GD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01) :228-241
[4]   Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray" [J].
Brans, B. ;
Bodei, L. ;
Giammarile, F. ;
Linden, O. ;
Luster, M. ;
Oyen, W. J. G. ;
Tennvall, J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (05) :772-786
[5]   Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP [J].
Breitz, H ;
Wendt, R ;
Stabin, M ;
Bouchet, L ;
Wessels, B .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) :225-230
[6]   The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships [J].
Brenner, DJ ;
Hlatky, LR ;
Hahnfeldt, PJ ;
Huang, Y ;
Sachs, RK .
RADIATION RESEARCH, 1998, 150 (01) :83-91
[7]   Investigation of the relationship between linear attenuation coefficients and CT Hounsfield units using radionuclides for SPECT [J].
Brown, Saxby ;
Bailey, Dale L. ;
Willowson, Kathy ;
Baldock, Clive .
APPLIED RADIATION AND ISOTOPES, 2008, 66 (09) :1206-1212
[8]   The radiobiology of conventional radiotherapy and its application to radionuclide therapy [J].
Dale, R ;
Carabe-Fernandez, A .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (01) :47-51
[9]   Dose-rate effects in targeted radiotherapy [J].
Dale, RG .
PHYSICS IN MEDICINE AND BIOLOGY, 1996, 41 (10) :1871-1884